SeekingAlpha · Aug 7, 2026
Wasatch Micro Cap Fund Q2 2026 Contributors And Detractors
Wasatch Micro Cap Fund's Q2 2026 report analyzes semiconductor gains and consumer sector challenges. Read the full analysis for more details.
TL
NASDAQ · TLSI
TriSalus Life Sciences, Inc.
Healthcare · Medical - Devices
$5.63
Down-$0.08 (-1.40%)
Updated Aug 14, 2026, 10:25 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 247.45M
- P/E ratio
- -4.6
- Dividend yield
- 0.00%
- 52-week range
- $2.20 – $7.95
- Volume
- 268.07K
- Avg. volume
- 137.4K
Price performance
TLSI price history
1M range · 21 trading sessions · Daily adjusted prices
TLSI closed at $5.63 after 21 trading sessions, up 29.13% for the selected period.
- Last close
- $5.63
- Period change
- +29.13%
- Period low
- $4.22
- Period high
- $5.74
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $5.74 | $5.91 | $5.57 | $5.63 | 268.07K |
| Aug 12, 2026 | $5.74 | $5.82 | $5.52 | $5.71 | 141.06K |
| Aug 11, 2026 | $5.53 | $5.85 | $5.42 | $5.74 | 252.19K |
| Aug 10, 2026 | $5.49 | $5.65 | $5.23 | $5.58 | 285.69K |
| Aug 7, 2026 | $4.94 | $5.7562 | $4.6719 | $5.61 | 700.85K |
| Aug 6, 2026 | $4.67 | $4.93 | $4.62 | $4.87 | 203.82K |
| Aug 5, 2026 | $4.76 | $4.78 | $4.44 | $4.62 | 290.22K |
| Aug 4, 2026 | $4.78 | $4.89 | $4.61 | $4.74 | 357.47K |
| Aug 3, 2026 | $4.51 | $4.79 | $4.4435 | $4.75 | 135.16K |
| Jul 31, 2026 | $4.55 | $4.59 | $4.38 | $4.54 | 190.52K |
| Jul 30, 2026 | $4.38 | $4.58 | $4.29 | $4.56 | 113.13K |
| Jul 29, 2026 | $4.34 | $4.50 | $4.30 | $4.38 | 136.8K |
| Jul 28, 2026 | $4.35 | $4.40 | $4.21 | $4.33 | 137.43K |
| Jul 27, 2026 | $4.26 | $4.413 | $4.12 | $4.32 | 94.41K |
| Jul 24, 2026 | $4.30 | $4.32 | $4.00 | $4.22 | 189.76K |
| Jul 23, 2026 | $4.12 | $4.30 | $4.01 | $4.27 | 262.04K |
| Jul 22, 2026 | $4.34 | $4.38 | $4.09 | $4.24 | 248.42K |
| Jul 21, 2026 | $4.33 | $4.38 | $4.23 | $4.34 | 201.82K |
| Jul 20, 2026 | $4.31 | $4.364 | $4.15 | $4.31 | 137.58K |
| Jul 17, 2026 | $4.30 | $4.41 | $4.225 | $4.29 | 145.72K |
| Jul 16, 2026 | $4.11 | $4.37 | $4.07 | $4.36 | 203.73K |
Latest TLSI news
The latest Smart Investors Daily articles mentioning TLSI.
Stock researchCompany · Overview
TLSI research
Overview
Company profile and research snapshot.
Company profile
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $10.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Lake Street | Buy | — |
| Mar 9, 2026 | Canaccord Genuity | Buy | — |
| Mar 6, 2026 | Canaccord Genuity | Buy | — |
| Dec 17, 2025 | Canaccord Genuity | Buy | — |
| Mar 28, 2025 | Canaccord Genuity | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 6, 2026
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsMary Szela - CEO, President & DirectorDavid...
Benzinga · Aug 6, 2026
TriSalus Life Sciences Affirms FY2026 Sales Guidance of $54.000M-$57.000M vs $52.396M Est
TriSalus Life Sciences (NASDAQ:TLSI) affirms FY2026 sales outlook from $54.000 million-$57.000 million to $54.000 million-$57.000 million vs $52.396 million estimate.
Benzinga · Aug 6, 2026
TriSalus Life Sciences Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $11.407M Beat $10.267M Estimate
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 40.74 percent increase over losses of $(0.27) per
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
